Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
24.25
-0.13 (-0.53%)
At close: May 9, 2025, 4:00 PM
24.30
+0.05 (0.21%)
After-hours: May 9, 2025, 7:59 PM EDT
Moderna Revenue
Moderna had revenue of $108.00M in the quarter ending March 31, 2025, a decrease of -35.33%. This brings the company's revenue in the last twelve months to $3.18B, down -38.35% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$3.18B
Revenue Growth
-38.35%
P/S Ratio
2.94
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MRNA News
- 2 days ago - Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 - Accesswire
- 8 days ago - Moderna: Regulatory Hurdles And Market Challenges Prompt Downgrade To Sell - Seeking Alpha
- 8 days ago - Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 - Benzinga
- 8 days ago - Moderna, Inc. (MRNA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Moderna Posts Loss, Citing Seasonality of Respiratory Business - WSJ
- 9 days ago - Moderna beats Wall Street estimates for first-quarter profit and sales - Reuters
- 9 days ago - Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates - Accesswire
- 9 days ago - Moderna Earnings Arrive During a Tough Time for the Stock - Barrons